{"data":{"type":"company_profile_ai","id":163242,"entity_id":"wefunder:company:163242","attributes":{"canonical_url":"https://wefunder.com/endosound","retrieval_urls":{"canonical":"https://wefunder.com/endosound","json":"https://wefunder.com/endosound.json","markdown":"https://wefunder.com/endosound.md","ai_json":"https://wefunder.com/endosound.ai.json","ai_text":"https://wefunder.com/endosound.ai.txt","changelog_json":"https://wefunder.com/endosound.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-07T03:04:28Z","generated_at":"2026-06-07T03:12:15Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":163242,"entity_id":"wefunder:company:163242","slug":"endosound","name":"EndoSound","tagline":"Advancing Access to High-Impact Endoscopic Ultrasound in GI ","location":"Portland, OR","website":"https://endosound.com","total_amount_raised":1705326,"total_investors":548,"is_funded":false,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 1705326","citation":"https://wefunder.com/endosound#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-08T03:04:28Z"},{"claim_id":"claim-total-investors","text":"Total investors: 548","citation":"https://wefunder.com/endosound#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-08T03:04:28Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 1705326","citation":"https://wefunder.com/endosound#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-08T03:04:28Z"},{"claim_id":"claim-total-investors","text":"Total investors: 548","citation":"https://wefunder.com/endosound#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-08T03:04:28Z"}],"company_claims":{"tagline":"Advancing Access to High-Impact Endoscopic Ultrasound in GI ","story":"Company OverviewEndoSound(R), Inc. is a medical technology company focused on expanding access to endoscopic ultrasound (EUS), a diagnostic modality used in gastrointestinal care. The company has developed a system designed to enable ultrasound capability using standard gastroscopes commonly found in endoscopy settings.Endoscopic ultrasound is widely used in hospital environments but is less commonly available in ambulatory surgical centers and community-based hospital settings due to cost, infrastructure, and training requirements. EndoSound’s approach is intended to address certain elements of these constraints; however, adoption, utilization, and clinical outcomes may vary across care settings.The company’s first-generation system has received FDA clearance. Regulatory clearance does not ensure clinical adoption, commercial success, or improved patient outcomes.The current offering is intended to support continued product development, manufacturing readiness, and commercialization of the company’s next-generation endoscopic ultrasound system.Selected Investment ConsiderationsThe following points summarize certain factors that may be relevant when evaluating the Company. These considerations are not exhaustive and should be reviewed in conjunction with the full offering materials.The company has developed an FDA-cleared first-generation system designed to enable ultrasound functionality using standard gastroscopesThe product is intended to integrate into existing endoscopy workflows without requiring dedicated echoendoscopesThe company is pursuing a model that includes both system sales and recurring procedure-based revenueEarly clinical use has provided operational feedback that informs ongoing product developmentMarket adoption is subject to a range of factors, including physician acceptance, training requirements, reimbursement dynamics, and institutional purchasing decisionsIndustry Context and ProblemEndoscopic ultrasound is a diagnostic procedure that combines standard endoscopy with ultrasound imaging, allowing physicians to evaluate the gastrointestinal tract and surrounding structures in greater detail than with standard endoscopy alone. It is used in the evaluation of certain GI cancers, lesions, and other conditions where additional imaging is needed to inform next steps.Access to EUS is largely concentrated in larger hospitals and academic medical centers. Traditional EUS systems typically require dedicated echoendoscopes, significant upfront capital investment, and physicians who have completed specialized training beyond standard endoscopy. Community hospitals and ambulatory surgery centers, where a substantial share of routine endoscopy takes place, often lack one or more of these requirements.When a patient's initial endoscopy occurs at one of these settings and ultrasound imaging is needed to evaluate a finding, that patient is generally referred to a separate facility. The referring site cannot complete the evaluation on its own. Depending on the provider and region, these referrals may result in scheduling delays, additional patient appointments, and a break in continuity of care.EndoSound has developed an FDA-cleared system intended to address this access gap at the point where endoscopy is already being performed. The system is designed to add ultrasound capability to standard gastroscopes that many facilities already own, rather than requiring the purchase of a traditional dedicated EUS system, which can cost approximately $450,000 or more. EndoSound's system is priced at approximately $60,000.The system is intended to integrate into existing endoscopy workflows without requiring new infrastructure or significant changes to room staffing and setup. EndoSound continues to refine its product based on direct feedback from physicians using the system in clinical practice. Actual integration, utilization, and physician adoption may differ across institutions, and there can be no assurance that future iterations will achieve intended performance or market acceptance.Development Status and TrajectoryThe company reports that its first-generation system has progressed through product development, regulatory clearance, and use in clinical settings.According to company-reported internal tracking, the system has been used in hundreds of procedures across 17 active clinical sites as part of routine endoscopy workflows. These figures have not been independently verified.Feedback from early clinical use has informed the design of a next-generation system. The transition from initial clinical use to broader commercialization is subject to additional development, manufacturing, and market factors, all of which involve uncertainty.Market OpportunityEndoSound has estimated its addressable market based on published upper endoscopy procedure volumes, site-of-care distribution, and internal assumptions regarding adoption and per-procedure pricing of approximately $650.Approximately 8 million upper endoscopy procedures are performed each year in the United States. According to the company, an estimated 80% of hospitals and 97% of ambulatory surgery centers do not currently offer EUS, primarily due to the capital requirements and infrastructure associated with traditional systems.Based on this landscape, EndoSound estimates its market opportunity as follows:Total Addressable Market (TAM): approximately $19 billionServiceable Addressable Market (SAM): approximately $7.2 billionInitial Serviceable Obtainable Market (SOM): approximately $1.8 billionThese estimates are derived from internal modeling using procedure volume data and pricing assumptions. They are intended to illustrate the scope of the opportunity as the company sees it and should not be interpreted as projections of future financial performance. Actual market opportunity may differ materially based on adoption rates, pricing, competition, and other factors outside the company's control.Clinical and Economic ConsiderationsThe company believes that expanding access to ultrasound-enhanced endoscopy may have clinical and economic implications at the point of care. EndoSound's system is designed to enable Echo-EGD, defined as a standard upper GI endoscopy enhanced with ultrasound imaging, in settings where traditional EUS systems are not deployed.The company references published data and internal estimates suggesting the following potential outcomes:Echo-EGD may identify pancreatic disease in approximately 40% of patients presenting with dyspepsiaIt may change clinical management in approximately 25% of cases compared to standard upper GI endoscopy aloneUse as a first-line diagnostic tool has the potential to shorten the diagnostic timeline from approximately 10 weeks to approximately 2 weeksEstimated savings of approximately $4,600 in insurance costs per episode of careEstimated savings of over $1,100 in patient out-of-pocket expenses per episode of careOutcomes may vary depending on patient population, provider expertise, and clinical setting. No assurance can be given that EndoSound's system will achieve similar results across all institutions or use cases, and these figures should not be interpreted as guarantees of clinical or financial performance.Business ModelEndoSound intends to generate revenue through two channels: an upfront system sale and recurring per-procedure usage fees.Facilities purchase the EndoSound system for approximately $60,000, compared to traditional EUS systems that often cost $450,000 or more and require dedicated scopesAfter installation, the company charges approximately $650 per procedure each time the system is used in clinical practiceThe company reports gross margins of approximately 95% on per-procedure revenueThis structure is intended to generate recurring revenue that grows alongside procedure volume at each installed site, without requiring additional capital equipment purchases. These figures reflect current pricing targets and internal estimates. Actual revenue, margins, and pricing may vary based on market conditions, customer agreements, and reimbursement dynamics.Commercial TractionThe company reports the following operational milestones, based on internal tracking that has not been independently verified:Hundreds of procedures completed using the first-generation system across 17 active clinical sitesRoughly 50 facilities have expressed preliminary interest or are in various stages of engagement regarding the next product iteration$3.5M raised in the company's initial round, including $1.4M through Wefunder$5M non-dilutive licensing and royalty agreement executed with a strategic partner for commercialization rights in ChinaEndoSound received ASGE and AGA Innovation of the Year recognition in 2022Expressions of interest from facilities do not constitute binding purchase commitments. Commercial adoption remains subject to individual purchasing decisions, clinical validation requirements, and operational considerations at each institution. Industry recognition does not imply endorsement of the company's securities or investment opportunity.Use of ProceedsThe company intends to use proceeds from this offering for purposes that may include:Commercial expansion and sales effortsManufacturing and supply chain developmentContinued product development and engineeringGeneral corporate and administrative expensesActual allocation of funds may vary based on operational priorities, market conditions, and other factors.ManagementEndoSound's leadership team includes individuals with backgrounds spanning clinical EUS practice, ultrasound engineering, and medical device commercialization. Prior experience does not guarantee future performance or the success of the company.Scott Aldrich Jr., Chief Executive Officer - Medical device executive with 20+ years in gastrointestinal devices. Previously held strategy and commercialization roles at MotusGI, Mauna Kea, and Pentax Medical.Stephen Steinberg, MD, Founder and Chief Medical Officer - GI physician with 40+ years of clinical and academic experience. Has performed thousands of EUS procedures, served as a key opinion leader in the field, and co-invented EndoSound's core technology.Scott Corbett, Founder and Chief Technology Officer - Biomedical engineer with 30+ years in ultrasound. Holds 19 patents, co-invented EndoSound's technology, and previously held engineering leadership roles at GE, Tyco Healthcare, and Sonivate.Paul Henwood, Chief Operating Officer - Operations executive with experience scaling early- and mid-stage technology companies. Began his career as an ultrasound transducer engineer and later served in senior leadership roles including CEO and President. Helped lead MicroConnex through operational growth and a successful exit.Josh Cohn, Chief Commercial Officer - Medtech commercial leader with 18 years of sales experience. Former National Sales Director at Pentax Medical, focused on EUS commercialization across hospitals and ambulatory surgery centers.Risk ConsiderationsAn investment in EndoSound involves a high degree of risk. These risks include, but are not limited to:Early-stage company risk and limited operating historyUncertainty of product adoption and market acceptanceRegulatory and compliance risksDependence on key personnelCompetition from existing and emerging technologiesReimbursement variability across healthcare systemsPotential need for additional capitalIlliquidity of the investmentInvestors should be prepared to lose their entire investment.Forward-Looking StatementsThis communication contains forward-looking statements, including statements regarding product development, market opportunity, and business strategy. These statements are based on current expectations and assumptions that involve risks and uncertainties.Actual results may differ materially from those expressed or implied in forward-looking statements. No assurance can be given that the Company will achieve its objectives or that any investment will result in a financial return.","quick_facts":["FDA Breakthrough Device and FDA cleared. 1000+ procedures performed with a 95%+ clinical acceptance","Co-Founder \u0026amp; CTO, sold last company MicroConnex, to Carlisle Interconnect Technologies","Raised $12M+ to date from GeoMedTech, AGA GI Fund, strategic partners, and founders","Hybrid go-to-market model: $60K system sale + $650 recurring revenue","Major GI Company paid $5M for licensing agreement","Significant IP with 10 awarded patents and 10 patent pending","GI Innovation of the Year 2022 - American Society for Gastrointestinal Endoscopy (ASGE)","Expanding into a $20.1B global market across gastrointestinal diagnostics and echo-endoscopy"]},"computed_metrics":{"total_amount_raised":1705326,"total_investors":548,"team_size":5,"featured_investor_count":6,"faq_count":5,"recent_post_count":10},"quick_facts":[{"claim_id":"claim-fact-1","value":"FDA Breakthrough Device and FDA cleared. 1000+ procedures performed with a 95%+ clinical acceptance","citation":"https://wefunder.com/endosound#claim-fact-1","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-2","value":"Co-Founder \u0026amp; CTO, sold last company MicroConnex, to Carlisle Interconnect Technologies","citation":"https://wefunder.com/endosound#claim-fact-2","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-3","value":"Raised $12M+ to date from GeoMedTech, AGA GI Fund, strategic partners, and founders","citation":"https://wefunder.com/endosound#claim-fact-3","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-4","value":"Hybrid go-to-market model: $60K system sale + $650 recurring revenue","citation":"https://wefunder.com/endosound#claim-fact-4","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-5","value":"Major GI Company paid $5M for licensing agreement","citation":"https://wefunder.com/endosound#claim-fact-5","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-6","value":"Significant IP with 10 awarded patents and 10 patent pending","citation":"https://wefunder.com/endosound#claim-fact-6","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-7","value":"GI Innovation of the Year 2022 - American Society for Gastrointestinal Endoscopy (ASGE)","citation":"https://wefunder.com/endosound#claim-fact-7","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"},{"claim_id":"claim-fact-8","value":"Expanding into a $20.1B global market across gastrointestinal diagnostics and echo-endoscopy","citation":"https://wefunder.com/endosound#claim-fact-8","observed_at":"2026-06-07T03:04:28Z","expires_at":"2026-06-14T03:04:28Z"}],"latest_fundraise":{"id":165727,"entity_id":"wefunder:fundraise:165727","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[{"investor_name":"Kingscrowd Capital","investor_entity_id":"wefunder:notable_investor:12685","memo_url":"https://wefunder.com/memos/feed/185311-endosound-investment-memo","claim_id":"claim-investor-memo-1","citation":"https://wefunder.com/endosound#claim-investor-memo-1","paid_for_by_company":false}],"team":[{"id":5559669,"entity_id":"wefunder:company_role:5559669","name":"Scott Aldrich Jr","title":"Chief Executive Officer","role":"founder","profile_url":"https://wefunder.com/scott.aldrich.jr"},{"id":5602078,"entity_id":"wefunder:company_role:5602078","name":"Stephen Steinberg","title":"Founder \u0026 Chief Medical Officer","role":"founder","profile_url":"https://wefunder.com/stephen.steinberg"},{"id":5602085,"entity_id":"wefunder:company_role:5602085","name":"Scott Corbett","title":"Founder \u0026 Chief Technology Officer","role":"founder","profile_url":"https://wefunder.com/scott.corbett"},{"id":5142417,"entity_id":"wefunder:company_role:5142417","name":"Josh Cohn","title":"Chief Commercial Officer","role":"founder","profile_url":"https://wefunder.com/josh.cohn.2"},{"id":5724019,"entity_id":"wefunder:company_role:5724019","name":"Elizabeth Ettling","role":"founder","profile_url":"https://wefunder.com/elizabeth.ettling"}],"featured_investors":[{"id":12254,"entity_id":"wefunder:company_investor_profile:12254","name":"Kingscrowd Capital","bio":"Kingscrowd Capital is the first Data-Driven Fund in the Online Private Market.","profile_url":"https://wefunder.com/kingscrowd.capital.3","endorsement_quote":"Investing in EndoSound is a bet on accessibility, affordability and market expansion, not medical breakthroughs. While risks remain, the upside case is compelling. By opening a cheaper, more accessible category in a multi-billion-dollar market, EndoSound could become the go-to EUS provider for ASCs and smaller hospitals nationwide. Strong clinical endorsements, early revenue traction, and a clear go-to-market strategy create a credible path to scale. For investors seeking a lower-risk medtech entry point with asymmetric upside potential, EndoSound offers a differentiated play on cost-driven healthcare adoption.","memo_url":"https://wefunder.com/memos/feed/185311-endosound-investment-memo"},{"id":11548,"entity_id":"wefunder:company_investor_profile:11548","name":"Chris Oubre","bio":"Chris brings over 28 years of leadership experience in healthcare management, operations, and information services. His career has been defined by a commitment to building high-performing teams that drive scalable, efficient healthcare platforms. As Co-Founder, President, and COO of MetaPhy Health, Chris has helped shape the company’s strategic vision and operational execution. Prior to founding MetaPhy, he served as the first Chief Information Officer at Covenant Surgical Partners, later transitioning into the role of Chief Operating Officer. In addition to his executive roles, Chris is an active investor and operating partner in several early-stage healthcare ventures. His investment in EndoSound stems from a deep belief in the transformative potential of its technology in the GI space","profile_url":"https://wefunder.com/chris.oubre","endorsement_quote":"\"I’ve been fortunate to work with and invest in a number of early-stage healthcare companies, and I’ve seen what both success and failure look like. I invested in EndoSound because of the measurable impact it's already had in GI. The team is well-positioned to advance this technology, and as someone who understands the operational needs of surgery centers, I know how critical it is to expand service lines and improve efficiency. Moving EUS into the ASC setting achieves both.\""},{"id":11550,"entity_id":"wefunder:company_investor_profile:11550","name":"Morris Sandler","bio":"Mr. Sandler is a successful entrepreneur, strategist, Board Member, capital raiser and executive leader. He has four decades of experience in financial services and venture capital. Mr. Sandler is a builder of more than 50 early-stage companies and helped finance over $275 million in equity.","profile_url":"https://wefunder.com/morris.sandler.1","endorsement_quote":"\"An investment into EndoSound was an easy decision for me. My initial investment was modest and was to support a dear friend I have known for over 40 years, the Co-Founder of EndoSound, Dr. Steve Steinberg. I’ve had the pleasure of seeing Steve's dream of democratizing EUS go from the back of a napkin, to FDA cleared and commercially available. For decades, I’ve seen first-hand what successful teams and companies look like. EndoSound has continued to demonstrate success, hit major milestones and I continue to invest at every opportunity because of the credibility they have earned along the way and the incredible impact they are making on the GI community.”"},{"id":11553,"entity_id":"wefunder:company_investor_profile:11553","name":"Bora Gumustop, MD","bio":"Dr. Bora Gumustop is a practicing Interventional Gastroenterologist. He is the co-inventor and co-founder of the Beacon Endoscopic Ultrasound needle that was acquired by Medtronic, then Covidien, in 2013.","profile_url":"https://wefunder.com/bora.gumustop.md","endorsement_quote":"“As the co-inventor of the Beacon Endoscopic needle, I know the hard work that is required for an early-stage company to get a product from bench to bedside. The EndoSound mission resonated with me immediately and that is why I was so excited about investing. I’m excited to see how they continue to disrupt the market and gain market share.”"},{"id":11554,"entity_id":"wefunder:company_investor_profile:11554","name":"Matthew McDonald, DO","bio":"Dr. McDonald is a Bariatric Surgeon who practices in Albany, New York.","profile_url":"https://wefunder.com/matthew.mcdonald.do","endorsement_quote":"“For smaller hospitals and ASC’s, traditional EUS equipment is expensive and the cost to acquire is prohibitive. The EVS is a fraction of the cost of traditional systems and is creating greater access to this critical procedure. The best part about this is how both patients and providers will benefit from this while the overall cost of healthcare is reduced”"},{"id":13511,"entity_id":"wefunder:company_investor_profile:13511","name":"Chris Oubre","bio":"Chris Oubre is a healthcare executive, investor and entrepreneur with extensive experience building and scaling innovative care delivery models across chronic care management, digital health, and specialty practice support.","profile_url":"https://wefunder.com/chris.oubre.1","endorsement_quote":"I’m investing in EndoSound because I believe they are solving a meaningful problem in Gastroenterology by expanding access to endoscopic ultrasound (EUS) and bringing advanced capabilities into new care settings. Their technology has the potential to improve clinical outcomes while also creating operational and financial value for providers. After spending time with the team and understanding the vision, I believe they have the opportunity to redefine how EUS is delivered."}],"relationships":[{"source_entity_id":"wefunder:company:163242","relation":"has_team_member","target_entity_id":"wefunder:user:4526209","target_url":"https://wefunder.com/scott.aldrich.jr"},{"source_entity_id":"wefunder:company:163242","relation":"has_team_member","target_entity_id":"wefunder:user:4721385","target_url":"https://wefunder.com/stephen.steinberg"},{"source_entity_id":"wefunder:company:163242","relation":"has_team_member","target_entity_id":"wefunder:user:4784921","target_url":"https://wefunder.com/scott.corbett"},{"source_entity_id":"wefunder:company:163242","relation":"has_team_member","target_entity_id":"wefunder:user:4450807","target_url":"https://wefunder.com/josh.cohn.2"},{"source_entity_id":"wefunder:company:163242","relation":"has_team_member","target_entity_id":"wefunder:user:4737259","target_url":"https://wefunder.com/elizabeth.ettling"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:12685","target_url":"https://wefunder.com/kingscrowd.capital.3"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:15290","target_url":"https://wefunder.com/chris.oubre"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:15292","target_url":"https://wefunder.com/morris.sandler.1"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:15295","target_url":"https://wefunder.com/bora.gumustop.md"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:15296","target_url":"https://wefunder.com/matthew.mcdonald.do"},{"source_entity_id":"wefunder:company:163242","relation":"has_featured_investor","target_entity_id":"wefunder:user:4760566","target_url":"https://wefunder.com/chris.oubre.1"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:328264","target_url":"https://wefunder.com/feed/328264"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:323611","target_url":"https://wefunder.com/feed/323611"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:320462","target_url":"https://wefunder.com/feed/320462"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:317623","target_url":"https://wefunder.com/feed/317623"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:220159","target_url":"https://wefunder.com/feed/220159"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:219114","target_url":"https://wefunder.com/feed/219114"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:217023","target_url":"https://wefunder.com/feed/217023"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:216701","target_url":"https://wefunder.com/feed/216701"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:213953","target_url":"https://wefunder.com/feed/213953"},{"source_entity_id":"wefunder:company:163242","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:213396","target_url":"https://wefunder.com/feed/213396"},{"source_entity_id":"wefunder:company:163242","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:165727"}],"faq":[{"question":"what type of investment is this? equity? interest only investment? any financial details would be helpful","answer":"Thank you for your interest in EndoSound. This is a convertible note. https://help.wefunder.com/#/contract/295251-convertible-note Once you click the reserve button, the terms of the convertible note can be found on the right-hand side. Here is a link: https://wefunder.com/endosound/invest Should you have any additional questions, please do not hesitate to reach out. The EndoSound Team"},{"question":"Hello Josh, I'm not particularly worried about your Debt Ratio of 199% at this stage of the company's lifecycle, just because with a Cash to Assets ratio of 47%, and future positive returns, the Debt Ratio can eventually be slashed down over time and eventually paid off with i...","answer":"Great question—happy to clarify. The reported 80% gross margin includes licensing revenue. When isolating product sales and excluding non-cash items like depreciation, as well as warranty reserves and inventory write-offs, our 2024 product gross margin was approximately 68%. Last year’s gross margin was impacted by early-stage commercialization factors, including lower purchasing volumes, higher inbound shipping costs, and the operational dynamics typical of a company in its first year of rev..."},{"question":"SHARE PRICE","answer":"Since this is a convertible note, there isn’t a fixed share price at the time of investment. Instead, the investment will convert into equity during a Series B round—it will be at a 20% discount to that round’s share price or at a valuation cap of $45M, whichever provides the better conversion terms."},{"question":"I am a pulmonologist, and I am familiar with EBUS. It appears that your device is a disposable product. What is the cost of the product, and is this a reimbursable expense to the endoscopy suite? Does Medicare recognized the importance of EBUS and reimburse enough to cover the...","answer":"Hi Howard, Thanks for your thoughtful question. While our platform is currently focused on GI applications, we are actively exploring EBUS as a potential addition to our portfolio and have already conducted some early technical feasibility work. To clarify our design: our system features a reusable ultrasound transducer (with no working channels), paired with a single-use device that connects the transducer to the endoscope and controls the needle—eliminating the need for an elevator mechanis..."},{"question":"Hi EndoSound Team, I’m Zac Stahlhut with D3VC, a venture fund specializing in investment crowdfunding. Our team is conducting its due diligence and has two follow-up questions regarding the clinical application of your technology. First, your materials highlight a significant ...","answer":"Hi Zac- I’m Steve Steinberg, co-founder and Chief Medical Officer for EndoSound. Thanks for your insightful questions: 1. Diagnostic Timeline: a. Abdominal Pain and Dyspepsia: 25 years ago, Anand Sahai and a group of equally prominent luminaries in EUS demonstrated a 40% “find” rate when endoscopic ultrasound was added to a traditional upper endoscopic exam (EGD)—conditions that would not have been discovered with the standard EGD alone. (EUS to detect evidence of pancreatic disease in patien..."}],"recent_posts":[{"id":328264,"entity_id":"wefunder:feed_item:328264","title":"EndoSound®: We Are Live!","preview":"Welcome to our Crowdfunding Round!FDA cleared. Hundreds of procedures with Gen 1. Now, Gen 2 underway.The EndoSound Vision System (EVS®) was developed to convert a standard gastroscope into an endoscopic ultrasound system. In December 2023, the EVS received FDA clearance.The EVS Gen 1 has been used in hundreds of procedures across hospital and ambulatory surgery center settings.That clinical experience informed the EVS Gen 2. The updated system incorporates a 50% smaller footprint, enhanced d...","published_at":"2026-06-03T14:23:46Z","canonical_url":"https://wefunder.com/feed/328264"},{"id":323611,"entity_id":"wefunder:feed_item:323611","title":"The EVS Gen 2: “Way easier. Very easy to maneuver. Image is great.\"","preview":"That was Dr. Stuart Akerman's reaction last week, trying the EVS® Gen 2 for the first time. He's one of our longest-tenured EVS users.EVS Gen 2 introduces the EVS SideBeam™, a new disposable that integrates our ultrasound probe directly with your existing endoscope. No new scope investment required. We also built a new EVS Probe with a single-crystal transducer, designed for excellent image quality.The first EVS Gen 2 cases in the US are in. So much more to come.","published_at":"2026-05-19T15:34:18Z","canonical_url":"https://wefunder.com/feed/323611"},{"id":320462,"entity_id":"wefunder:feed_item:320462","title":"The EndoSound Vision System Generation 2 is here","preview":"We've given sneak peaks over the past few weeks, so without further ado... We took everything we learned from hundreds of procedures in the field with EVS® Gen 1 — and we built what comes next.Gen 2 introduces the EVS SideBeam™, a new disposable that integrates our ultrasound probe directly with your existing endoscope. No new scope investment required.We’ll also introduce a new EVS Probe built with a single-crystal transducer, designed to deliver excellent image quality at the point of care....","published_at":"2026-05-12T18:05:58Z","canonical_url":"https://wefunder.com/feed/320462"},{"id":317623,"entity_id":"wefunder:feed_item:317623","title":"Busy past few days...","preview":"Yesterday was the last day of Digestive Disease Week (DDW) in Chicago — and it did not disappoint. DDW is one of the largest academic conferences and tradeshows in our field. It's busy under normal circumstances, but we launched the EVS Gen 2 there, so these were anything but normal circumstances. We had a great show and tremendous interest from GIs across the US and around the globe.One of the highlights of the meeting was a Sunday morning session where leaders in the field gathered to discu...","published_at":"2026-05-06T14:47:25Z","canonical_url":"https://wefunder.com/feed/317623"},{"id":220159,"entity_id":"wefunder:feed_item:220159","title":"Thank you from all of us at EndoSound!","preview":"Thank you from all of us at EndoSound!","published_at":"2025-11-13T16:26:36Z","canonical_url":"https://wefunder.com/feed/220159"},{"id":219114,"entity_id":"wefunder:feed_item:219114","title":"Less than 10 hours to go to invest...","preview":"In less than 10 hours, our Wefunder campaign will close, and the opportunity to invest at this stage will be gone.More than 560 investors have already joined us, contributing almost $1.5M helping us exceed our goal showing how much our message resonates with our investor community.Thank you, thank you, thank you!!","published_at":"2025-11-10T19:19:57Z","canonical_url":"https://wefunder.com/feed/219114"},{"id":217023,"entity_id":"wefunder:feed_item:217023","title":"Most Raised again this week! Just a little more to go...","preview":"Thank you for helping us become \"Most Raised\" on the platform again. We keep saying how we are overwhelmed and humbled by the support, and we really mean it.We've been active in the market, assisting with current customers, installing new systems at new clients, and helping spread the word about endoscopic ultrasound (EUS) in the ambulatory surgical center, or EUS in the ASC. Driving access to this technology is our mission.These are final days of our Wefunder campaign. Come join us!We are no...","published_at":"2025-11-06T15:55:17Z","canonical_url":"https://wefunder.com/feed/217023"},{"id":216701,"entity_id":"wefunder:feed_item:216701","title":"🚀 Milestone Alert: New Country. New Physician. Two Hospitals. One Day.","preview":"The versatility and portability of the EndoSound Vision System (EVS) were on full display yesterday in the Dominican Republic.Our Director of Clinical Support, Kenneth Scruggs, arrived Monday, completed four procedures (1 FNB and 3 Echo-Endoscopies) across two hospitals, and demonstrated how seamlessly the EVS can be transported, set up, and used.Even more impressive — a physician using the system for the first time performed procedures flawlessly in facilities that previously had no access t...","published_at":"2025-11-05T19:38:25Z","canonical_url":"https://wefunder.com/feed/216701"},{"id":213953,"entity_id":"wefunder:feed_item:213953","title":"Closing Soon: Just days to go in the community raise!","preview":"EndoSound® has reached milestones that few medtech companies achieve this early. With FDA clearance validating safety and effectiveness, reimbursement securing financial viability for providers, and $1M in revenue since launch from real-world use, the company has already proven both clinical and commercial traction. Physicians have completed more than 650 procedures with a 95% clinical acceptance rate. Global demand is taking shape with a $5M licensing deal already secured.Investors have alre...","published_at":"2025-10-30T16:11:07Z","canonical_url":"https://wefunder.com/feed/213953"},{"id":213396,"entity_id":"wefunder:feed_item:213396","title":"Out in the field, spreading the word...","preview":"Yesterday, the American College of Gastroenterology (ACG) annual conference ended. We were there alongside many other companies and we're always pleased with the interest the EVS device generates and how many physicians perk up when they see us present it. Especially at a conference like this that has so many options to claim people's time. We had Steve Steinberg, one of our co-founders, there to talk doctor-to-doctor as well, which always helps.The Wefunder campaign is entering its final day...","published_at":"2025-10-29T16:19:40Z","canonical_url":"https://wefunder.com/feed/213396"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-07T03:12:15Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T03:04:28Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-06-02T20:58:53Z","as_of":"2026-06-07T03:12:15Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-06-02T20:58:53Z","as_of":"2026-06-07T03:12:15Z","confidence":"medium"}}}}}}